MIL •
Healthcare •
Biotechnology •
Quote as of 07/30/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeMIL
Market Capitalization10,028 mln
Float192 mln
Earnings Date08/04/2026
EPS
1.22
Stretched
P / E
42.39
High premium
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-2.8
Likely reliable
Relative Strength
75
/ 100
Strongly outperforming
Debt / Equity
0.23
Very low leverage
Business Description
BioMarin is a California-based pharmaceutical company founded in 1996 that focuses on creating treatments for rare and life-threatening diseases. It sells several approved medicines targeting conditions such as certain bone growth disorders, inherited metabolic diseases, and enzyme deficiencies, with products available across North America, Europe, Latin America, the Middle East, and the Asia Pacific region. The company also has a pipeline of new treatments in development, including therapies for growth disorders and Duchenne muscular dystrophy, and distributes its products through hospitals, specialty pharmacies, and wholesale partners worldwide.
